A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The "DURGA" Trial)

Trial Profile

A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The "DURGA" Trial)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Viagenpumatucel-L (Primary) ; Nivolumab
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DURGA
  • Sponsors Heat Biologics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Mar 2017 Interim results from the phase II portion published in a Heat Biologics media release.
    • 13 Mar 2017 Results published in a Heat Biologics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top